Siegel JS, Liston C, Nicol GE, Carhart-Harris RL, Bogenschutz MP. The science of psychedelic medicine. Nat Med. 2026;32(2):449-462. doi:10.1038/s41591-025-04194-5
Rucker JJ, Mantingh T, Kerr-Gaffney J, Bird C, Chu P, Modlin NL, Campbell-Coker K, Hambleton S, Seath P, Hignett R, Fennema D, Hampsey E, Tsapekos D, Thomas RJ, Cattell J, Jafari H, Day C, Borissova A, Lloyd M, Boardman-Pretty T, Seynaeve M, Askari F, Creed M, Baxter L, Rifkin-Zybutz R, Butler M, Jelen LA, Carter B, Young AH. Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial. Nat Med. 2026 Aug 6. doi: 10.1038/s41591-026-04541-0. Epub ahead of print. PMID: 42562964.
Girn M, Doss MK, Roseman L, Preller KH, Palhano-Fontes F, Pasquini L, Barrett FS, Mallaroni P, Mason NL, Timmermann C, McCulloch DE, Fisher PM, Winston BS, Moujaes F, Muller F, Liechti ME, Vollenweider FX, Ramaekers JG, Kuypers K, Araujo DB, Sporns O, Siegel J, Dosenbach N, Nutt DJ, Carhart-Harris RL, Stamatakis EA, Bzdok D. An international mega-analysis of psychedelic drug effects on brain circuit function. Nat Med. 2026 Apr;32(4):1543-1554. doi: 10.1038/s41591-026-04287-9. Epub 2026 Apr 6. PMID: 41942645; PMCID: PMC13099416.
Stoliker D, Novelli L, Khajehnejad M, Biabani M, Greaves MD, Barta T, Williams M, Chopra S, Bazin O, Simonsson O, Chambers R, Barrett FS, Deco G, Preller KH, Carhart-Harris RL, Seth AK, Sundram S, Egan GF, Razi A. Psychedelics align brain activity with context. Nature. 2026 Aug;656(8129):936-947. doi: 10.1038/s41586-026-10910-z. Epub 2026 Aug 19. PMID: 42618786; PMCID: PMC13518247.
Lyons T, Spriggs M, Kerkelä L, Rosas FE, Roseman L, Mediano PAM, Timmermann C, Oestreich L, Pagni BA, Zeifman RJ, Hampshire A, Trender W, Douglass HM, Girn M, Godfrey K, Kettner H, Sharif F, Espasiano L, Gazzaley A, Wall MB, Erritzoe D, Nutt DJ, Carhart-Harris RL. Human brain changes after first psilocybin use. Nat Commun. 2026 May 5;17(1):3977. doi: 10.1038/s41467-026-71962-3. PMID: 42086570; PMCID: PMC13144397.
Pettorruso M, d’Andrea G, Inserra A, et al. Mechanistic insights toward dissociating therapeutic from psychedelic effects: bridging the gap between psychedelic research and mental health care. Transl Psychiatry. 2026;16:458. doi:10.1038/s41398-026-04203-2.
Shao LX, Liao C, Davoudian PA, Savalia NK, Jiang Q, Wojtasiewicz C, Tan D, Nothnagel JD, Liu RJ, Woodburn SC, Bilash OM, Kim H, Che A, Kwan AC. Psilocybin’s lasting action requires pyramidal cell types and 5-HT2A receptors. Nature. 2025 Jun;642(8067):411-420. doi: 10.1038/s41586-025-08813-6. Epub 2025 Apr 2. Erratum in: Nature. 2025 Oct;646(8087):E33. doi: 10.1038/s41586-025-09671-y. PMID: 40175553; PMCID: PMC12188471.
Romeo B, Kervadec E, Fauvel B, Strika-Bruneau L, Amirouche A, Bezo A, Piolino P, Benyamina A. The intensity of the psychedelic experience is reliably associated with clinical improvements: A systematic review and meta-analysis. Neurosci Biobehav Rev. 2025 May;172:106086. doi: 10.1016/j.neubiorev.2025.106086. Epub 2025 Mar 1. PMID: 40031999.
Puigseslloses P, Nadal-Gratacós N, Fumàs B, Modenutti CP, Pottie E, Ortigosa JR, Pablo-Quesada A, Riera-Colomer C, Ettcheto M, Berzosa X, Pubill D, Stove C, Escubedo E, López-Arnau R. Neuropharmacology of halogenated DMT analogs: psychoplastogenic and antidepressant properties of 5-Br-DMT, a psychedelic derivative with low hallucinogenic potential. Mol Psychiatry. 2026 Mar;31(3):1733-1745. doi: 10.1038/s41380-025-03308-2. Epub 2025 Oct 21. PMID: 41120735; PMCID: PMC12916285.
Agrawal R, Gillie D, Mungenast A, Chytil M, Engel S, Wu MC, Rasmussen K, Salinas E, Olson DE. Zalsupindole is a Nondissociative, Nonhallucinogenic Neuroplastogen with Therapeutic Effects Comparable to Ketamine and Psychedelics. ACS Chem Neurosci. 2025 Nov 19;16(22):4388-4399. doi: 10.1021/acschemneuro.5c00667. Epub 2025 Oct 13. PMID: 41078264.
Cao D, Yu J, Wang H, Luo Z, Liu X, He L, Qi J, Fan L, Tang L, Chen Z, Li J, Cheng J, Wang S. Structure-based discovery of nonhallucinogenic psychedelic analogs. Science. 2022 Jan 28;375(6579):403-411. doi: 10.1126/science.abl8615. Epub 2022 Jan 27. PMID: 35084960.
Rajwani K, Jacobs E, Bruce L, Hokanson J, Almonte MT, Feroz F, Waldman E, Cheung K, Levy N, Savulescu J, Singh I, Yaden DB, Earp BD. Clinical psychedelic research in adolescents: a scoping review and overview of ethical considerations. Lancet Child Adolesc Health. 2025 Oct;9(10):744-752. doi: 10.1016/S2352-4642(25)00208-1. PMID: 40908054.
Simonsson O, Mosing MA, Osika W, Ullén F, Larsson H, Lu Y, Wesseldijk LW. Adolescent Psychedelic Use and Psychotic or Manic Symptoms. JAMA Psychiatry. 2024 Jun 1;81(6):579-585. doi: 10.1001/jamapsychiatry.2024.0047. PMID: 38477889; PMCID: PMC10938246.
Farah R, Kerns AF, Murray AC, Holstege CP. Psilocybin exposures reported to U.S. poison centers: national trends over a decade. J Adolesc Health. 2024;74(5):1053-1056. doi:10.1016/j.jadohealth.2024.01.027
Yu ZP, Zhang ZY, Li Q, Hu YF, Zhang T, Zhang XQ, Wang ZC, Zhou WH, Shen HW. Adolescent exposure to the psychedelic 25C-NBOMe in rats induces lasting competitive avoidance through disrupted hippocampal-prefrontal synchrony. Nat Neurosci. 2026 Sep;29(9):2249-2260. doi: 10.1038/s41593-026-02369-y. Epub 2026 Jul 20. PMID: 42477457.
Carbonaro TM, Bradstreet MP, Barrett FS, MacLean KA, Jesse R, Johnson MW, Griffiths RR. Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. J Psychopharmacol. 2016 Dec;30(12):1268-1278. doi: 10.1177/0269881116662634. Epub 2016 Aug 30. PMID: 27578767; PMCID: PMC5551678.
Hinkle JT, Graziosi M, Nayak SM, Yaden DB. Adverse events in studies of classic psychedelics: a systematic review and meta-analysis. JAMA Psychiatry. 2024;81(12):1225-1235. doi:10.1001/jamapsychiatry.2024.2546.
Konstantinou GN, Kloiber S. Psilocybin as an emerging anxiolytic: mechanisms, evidence, and open questions. Neuropsychopharmacology. Published online September 6, 2026. doi:10.1038/s41386-026-02551-7
Basargin AG, Domokos A, Hennessey JJ, Aarrestad IK, Sambyal R, Khatib YA, Krüger J, Dunlap LE, Carter SJ, Rebek IA, McKee JL, Schalk SS, Liu M, Fettinger JC, Gonzalez MA, Potluri A, Tantillo DJ, Fiehn O, McCorvy JD, Olson DE. Deconstruction of lysergic acid diethylamide. Proc Natl Acad Sci U S A. 2026 Sep 22;123(38):e2603412123. doi:10.1073/pnas.2603412123. Epub 2026 Sep 8. PMID: 42709856.
Heles M, Pasvolsky L, Sathishkumar H, Naara S, Vu Y, Stewart CL, Xie T, Gleber-Netto FO, McCarthy W, Yaniv D, Kamal SS, Elahi H, Zhu P, Uhelski ML, Chatwin J, Lara A, Stolley DL, Migden MR, Lee ZH, Thevasagayampillai S, Gunaratne PH, Ait-Ahmad K, Kuykendall MJ, Eksi SE, Cohen L, Borniger JC, Gottlieb E, Jones GH, Dougherty PM, Amit M. Psilocybin prevents chemotherapy-induced peripheral neuropathy through mitochondrial trafficking preservation. Science. 2026 Sep 3;393(6815):eaec6116. doi: 10.1126/science.aec6116. Epub 2026 Sep 3. PMID: 42691184.
Sikka P, Ngo MC, Hu S, Wilkerson TB, Shull M, Imbordino K, Ishii T, Kawai M, Deverett B, Chow HS, Heifets BD. Feasibility of a Multicomponent Protocol to Promote Dreaming during Surgical Anesthesia. Anesthesiology. 2026 Jul 1;145(1):21-36. doi: 10.1097/ALN.0000000000005968. Epub 2026 Feb 3. PMID: 41632715.
Nagele P, Duma A, Kopec M, Gebara MA, Parsoei A, Walker M, Janski A, Panagopoulos VN, Cristancho P, Miller JP, Zorumski CF, Conway CR. Nitrous Oxide for Treatment-Resistant Major Depression: A Proof-of-Concept Trial. Biol Psychiatry. 2015 Jul 1;78(1):10-18. doi: 10.1016/j.biopsych.2014.11.016. Epub 2014 Dec 9. PMID: 25577164.
Nagele P, Palanca BJ, Gott B, Brown F, Barnes L, Nguyen T, Xiong W, Salloum NC, Espejo GD, Lessov-Schlaggar CN, Jain N, Cheng WWL, Komen H, Yee B, Bolzenius JD, Janski A, Gibbons R, Zorumski CF, Conway CR. A phase 2 trial of inhaled nitrous oxide for treatment-resistant major depression. Sci Transl Med. 2021 Jun 9;13(597):eabe1376. doi: 10.1126/scitranslmed.abe1376. PMID: 34108247.
Zorumski CF, Cichon J, Izumi Y, Zeffiro T, Mennerick S, Nagele P, Conway CR. Rapid antidepressant potential of nitrous oxide: current state and major questions. Mol Psychiatry. 2026 Jun;31(6):3022-3032. doi: 10.1038/s41380-025-03439-6. Epub 2025 Dec 29. PMID: 41461923; PMCID: PMC13190246.
Myles PS, Kulkarni J, Kasza J, Wallace S, Deng C, Turbić A, Aykanat V, Conway CR, Brown F, Lee R, Gibbons RD, Nagele P. Antidepressant Effects of Nitrous Oxide in Major Depressive Disorder: A Phase 2b Randomized Clinical Trial. Biol Psychiatry Glob Open Sci. 2025 Apr 15;5(4):100504. doi: 10.1016/j.bpsgos.2025.100504. PMID: 40503328; PMCID: PMC12155549.
Armstrong SB, Levin AW, Sepeda ND, Shaub H, Hunter T, Douglas A, Lancelotta R, Davis AK. Safety, feasibility, and preliminary clinical outcomes of psilocybin-assisted therapy for veterans with severe, treatment-resistant PTSD: an open-label pilot clinical trial. Commun Med (Lond). 2026 Jul 30;6(1):411. doi: 10.1038/s43856-026-01767-4. PMID: 42533157; PMCID: PMC13424359.